Making the Difference in Cell and Gene Therapy
OXFORD BIOMEDICA
What We Do
At Oxford Biomedica, we partner with cell and gene therapy companies to provide innovative, end-to-end adeno-associated virus (AAV) platform process development and industry-leading manufacturing services to deliver life-saving and life-altering treatments to all.
HIGH YIELD HIGH QUALITY CONSISTENCY
What We Do
We offer thoughtful solutions leveraging the inAAVate™ platform, our experience, and technical expertise to ensure that all AAV products provide the
- high yield
- high quality
- consistency
needed to be successful in the clinic.
EXCEPTIONAL VALUE EFFICIENCY INDUSTRY EXCELLENCE
What We Do
From construct and plasmid design through full-scale commercialization, we deliver
- exceptional value
- efficiency
- industry excellence
We are your trusted partners.
Technical Expertise in AAV Manufacturing
The Game Changing Engine—
The inAAVate™ platform provides high-yield, high-quality product, giving you more of what you need in smaller batch sizes
Our suite of services delivers
-
high titer
Achieved >1E15 vg/L bioreactor titer
-
accelerated cell and gene therapy product development
Across a range of serotypes and genes of interest
-
high yield
Achieved >1E17 vg of drug substance per 500L batch equivalent
-
high product quality
Demonstrated >90% full AAV vectors
-
proven scalability
Up to 2,000L scale
- So you can stay ahead of the game.
Our Approach
Our highly accomplished team members bring expansive experiences, enabling us to offer
HIGH PERFORMANCE
>1E15 vg/L bioreactor titer demonstrated in >10 serotypes and multiple genes of interest
HIGH QUALITY
>90% full AAV vector achieved
CONTINUOUS INNOVATION
>1E17 vg of drug substance from a single 500L bioreactor lot
ANALYTICAL DEVELOPMENT
>45 methods developed for full vector characterization, quality control, and stability testing
REGULATORY EXPERIENCE
6 successful IND/CTA submissions achieved
COMMERCIAL READINESS
500 to 2000L scale confirmed in our suite of services
Using the inAAVate™ platform,
we have successfully—and repeatedly—delivered exceptional product quality for numerous constructs bearing different genomes and AAV serotypes across different production scales.
Our CompanyMaximizing Production and Quality of AAV Cell and Gene Therapies
The inAAVate™ platform can
produce significantly higher titers of AAV drug substance per batch than traditional processes
conserve both time and resources
deliver the lowest cost per patient dose
Under these conditions, sufficient amounts of high-quality product are made in 500L batches, reducing or eliminating the need for pooling or scaling up.
Our proprietary process and patent families*
ensure high product quality and yield, guaranteeing delivery of your product exactly as intended to patients.
*Patents pending.
Together, we can maximize the potential impact of AAV gene therapies on patients’ lives.
The ultimate benefit is
- accelerating your drug development timeline
- getting your product to clinic and market faster, while achieving product quality that will increase the probability of success for IND and BLA approval
- offering the best value economics in the industry
Oxford Biomedica is committed to ensuring that your process development and manufacturing needs are met through all stages of your AAV product drug development.
Top